Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

Inclusion criteria

• Signed, informed consent.
• Men and women greater than or equal to 55 years of age.
• Recent development of RPED secondary to AMD.
• ETDRS best corrected visual acuities of 20/40 to 20/320 (letter score of 73 to 25) in the study eye.
• Willing and committed and able to return for all clinic visits and complete all study related procedures.

Exclusion criteria

• Any prior treatment for neovascular AMD except dietary supplements or vitamins. (for patients in the treatment naïve group only)
• Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.
• Total lesion size greater than 12 disc areas.
• Subretinal hemorrhage that is either 50% or more of the total lesion area or if the blood is under the fovea and is 1 or more disc areas in size in the study eye.
• Scar or fibrosis making up greater than 50% of the total lesion in the study eye.
• Scar, fibrosis or atrophy involving the center of the fovea.
• Presence of a retinal pigment epithelial tear.
• History of a vitreous hemorrhage within 4 weeks prior to initiation of the study.
• Presence of other causes of choroidal neovascular membrane other than AMD.
• History of clinical evidence of diabetic retinopathy, especially diabetic maculopathy or macular edema from other causes, including retinal vein occlusion or diabetes
• Prior vitrectomy surgery in the study eye.
• History of retinal detachment treatment in the study eye.
• History of macular hole in the study eye.
• Any intraocular/periocular surgery within 3 months of the initiation of the study.
• Prior trabeculectomy or filtering surgery in the study eye.
• Uncontrolled glaucoma, defined as a pressure greater than 25 mmHg despite treatment.
• Active intraocular inflammation.
• Active ocular/periocular infection.
• Any history of uveitis.
• Active scleritis or episcleritis.
• Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of YAG posterior capsulotomy) in the study eye.
• Previous radiation therapy in the region of the study eye.
• History of corneal transplant or corneal dystrophy in the study eye.
• Significant medial opacities including cataract that may interfere with visual acuity or fundus photography.
• Any disease or ocular condition which, in the opinion of the investigator could either increase in the risk to the subject beyond what is expected from a standard procedure of intraocular injections or which may be considered contraindicated for the use of the investigational drug (VEGF Trap).
• The use of long acting steroids systemically or intraocularly.
• Any history of allergy to Proviodine or fluorescein sodium.